ClinicalTrials.gg
RecruitingNCT05473624Updated Apr 15, 2025

Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors

A Phase 1 interventional study of HRS-1167 in Advanced Solid Tumors, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 20 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-15.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
153
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is designed to determine if treatment with HRS-1167 alone is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18;
  2. performance status 0-1;
  3. is not less than 12 weeks;
  4. Dose escalation and PK expansion part: Subjects diagnosed with advanced solid who are to standard therapies or for which no standard therapy exists;
  5. Efficacy expansion part:Ovarian Cancer、Breast Cancer、Pancreatic Cancer、Prostate Cancer or other cancer types with HRR gene mutation;
  6. At least one target lesion (except maintenance therapy);
  7. Adequate organ and marrow function as defined by the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Surgery or chemotherapy within 4 weeks of the first dose of study treatment;
  2. Subjects that are unable to swallow, or dysfunction of gastrointestinal absorption;
  3. Active // infection;
  4. Untreated and/or uncontrolled .
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
153 participants (estimated)

Study arms

  • Experimental
    HRS-1167

    Drug: HRS-1167

Interventions

  • Participants will receive HRS-1167.

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT) of HRS-1167

    Time frame: up to 24 days

  2. Maximum tolerated dose (MTD) of HRS-1167

    Time frame: up to 24 months

  3. Recommended Phase II Dose (RP2D) of HRS-1167

    Time frame: up to 24 months

  4. AEs+SAEs

    from the first drug administration to within 30 days for the last treatment dose

    Time frame: up to 24 months

Secondary outcomes

  1. Evaluation of pharmacokinetic parameter of HRS-1167: Cmax

    The concentration of HRS-1167 in plasma will be determined (Cmax will be derived).

    Time frame: At Cycle 0 Day 1, Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1 (each cycle is 21 days)

  2. Evaluation of pharmacokinetic parameter of HRS-1167: Tmax

    The concentration of HRS-1167 in plasma will be determined (Tmax will be derived).

    Time frame: At Cycle 0 Day 1, Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1 (each cycle is 21 days)

  3. Evaluation of pharmacokinetic parameter of HRS-1167: AUC

    The concentration of HRS-1167 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered.

    Time frame: At Cycle 0 Day 1, Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, and Cycle 4 Day 1 (each cycle is 21 days)

  4. Objective Response Rate (ORR)

    Complete response + Partial response (CR+PR) based on RECIST 1.1.

    Time frame: up to 24 months

  5. Disease control rate (DCR)

    Complete response + Partial response + Stable disease (CR+PR+SD) based on RECIST 1.1.

    Time frame: up to 24 months

  6. Duration of response (DoR)

    Time from documentation of tumor response to disease progression assessed among patients who had an objective response.

    Time frame: up to 24 months

  7. Progression Free Survival (PFS)

    Time from C1D1 to first assessment of disease progression or death, whichever is earlier.

    Time frame: up to 24 months

07

Study locations

20 of 20 sites recruiting
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing 100021, China
    Recruiting
  • Chongqing Cancer Hospital
    Chongqing, Chongqing 400030, China
    Recruiting
    • Yongsheng Li, Doctor · Principal investigator
  • Guangxi Medical University Affiliated Tumor Hosipital
    Nanning, Guangxi 530021, China
    Recruiting
    • He Wang, Doctor · Principal investigator
  • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
    Guangzhou, Guangzhou 510120, China
    Recruiting
    • Ying Wang, Doctor · Principal investigator
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150081, China
    Recruiting
    • Hui Chen, Doctor · Principal investigator
  • Henan Cancer Hospital
    Zhengzhou, Henan 450008, China
    Recruiting
    • Min Yan, Doctor · Principal investigator
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
    Recruiting
    • Jing Wang, Doctor · Principal investigator
  • Hunan Cancer Hospital
    Changsha, Hunan 410013, China
    Recruiting
    • Shusuan Jiang, Doctor · Principal investigator
  • The First Affiliated Hospital with Nanjing Medical University
    Nanjing, Jiangsu 210029, China
    Recruiting
    • Yongmei Yin, Doctor · Principal investigator
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330209, China
    Recruiting
    • Bin Fu, Doctor · Principal investigator
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
    Recruiting
    • Jiuwei Cui, Doctor · Principal investigator
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110001, China
    Recruiting
    • Funan Liu, Doctor · Principal investigator
  • Liaoning Cancer Hospital
    Shenyang, Liaoning 110042, China
    Recruiting
    • Danbo Wang, Doctor · Principal investigator
  • Qilu Hospital of Shandong University
    Jinan, Shangdong 250062, China
    Recruiting
    • Shuwen Yu, Doctor · Principal investigator
  • Shandong Cancer Hospital
    Jinan, Shangdong 250117, China
    Recruiting
    • Yuping Sun, Doctor · Principal investigator
  • Second Hospital of Shanxi Medical University
    Taiyuan, Shanxi 030001, China
    Recruiting
    • Wei Wang, Doctor · Principal investigator
  • Shanxi Provincial Cancer Hospital
    Taiyuan, Shanxi 030013, China
    Recruiting
    • Hongwei Zhao, Doctor · Principal investigator
  • The Affiliated Hospital of Southwest Medical University
    Luzhou, Sichuan 646099, China
    Recruiting
    • Qinglian Wen, Doctor · Principal investigator
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, Tianjin 300060, China
    Recruiting
    • Xu Wang, Doctor · Principal investigator
  • Zhejiang Cancer Hospital
    Hangzhou, Zhengjiang 310022, China
    Recruiting
    • Xiaojia Wang, Doctor · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2022 (actual). Primary completion is estimated for Dec 2026, 52 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2022
First posted
Jul 26, 2022
StartActual
Aug 23, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05473624
Responsible party
Sponsor
First posted
Jul 26, 2022
Start date
Aug 23, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 15, 2025

Study contacts

Quanren Wang, M.D
Contact
quanren.wang@hengrui.com
+86 18036618570

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PARP1 Inhibitor HRS-1167

Start the discussion